

CITATION REPORT

List of articles citing

Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease

DOI: 10.2215/cjn.02170218

Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 278-287.

Source: <https://exaly.com/paper-pdf/71819472/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
48	Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1241-1255	3.8	5
47	Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	5
46	Expanding the Toolbox for Reversal of Anticoagulation in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1769-1771	15.1	
45	Warfarin in nonvalvular atrial fibrillation-Time for a change?. <i>Seminars in Dialysis</i> , 2019 , 32, 520-526	2.5	4
44	Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 481-488	3.9	7
43	Anticoagulation in difficult settings RELOADED: Evidence for applicability of direct oral anticoagulants in patients with atrial fibrillation, renal impairment and cancer. <i>IJC Heart and Vasculature</i> , 2019 , 23, 100374	2.4	0
42	Anticoagulation in chronic kidney disease: from guidelines to clinical practice. <i>Clinical Cardiology</i> , 2019 , 42, 774-782	3.3	33
41	Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1293	5.6	1
40	Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. <i>Open Heart</i> , 2020 , 7, e001232	3	13
39	Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Renal Impairment. <i>Pharmacy (Basel, Switzerland)</i> , 2020 , 8,	2	4
38	Benefits and Risks of Anticoagulation in Dialysis Patients With Nonvalvular Atrial Fibrillation: Navigating Through Darkness. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 286-288	15.1	1
37	A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure. <i>Kidney International</i> , 2021 , 99, 1162-1172	9.9	2
36	Anticoagulation in hemodialysis: A narrative review. <i>Seminars in Dialysis</i> , 2021 , 34, 103-115	2.5	7
35	Review of Medical Therapies for the Management of Pulmonary Embolism. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	4
34	Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review. <i>Cardiovascular Therapeutics</i> , 2021 , 2021, 8886210	3.3	5
33	Anticoagulation Management In Hemodialysis Patients With Atrial Fibrillation: Evidence And Opinion. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	2
32	Nonvitamin K oral anticoagulants in cardiac surgery: What cardiothoracic surgeons need to know 2.0. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 ,	1.5	2

31	Integrated Care in Atrial Fibrillation: A Road Map to the Future. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007411	5.8	3
30	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	
29	Point-of-care testing technologies for the home in chronic kidney disease: a narrative review. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 2316-2331	4.5	4
28	Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1056-1066	1.9	1
27	Low-Molecular-Weight Heparin Anti-Xa Guided Reversal of Apixaban With Prothrombin Complex Concentrate in a Patient on Hemodialysis. <i>Journal of Pharmacy Practice</i> , 2021 , 8971900211044288	1.3	
26	Updates in periprocedural management of direct oral anticoagulants. <i>Current Opinion in Anaesthesiology</i> , 2020 , 33, 423-431	2.9	3
25	Anticoagulant strategies for the patient with chronic kidney disease. <i>Clinical Medicine</i> , 2020 , 20, 151-155	1.9	2
24	Extensive skin necrosis in an elderly woman on dabigatran. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	1
23	Efficacy and tolerance of selective and non-selective factor Xa inhibitors in the prevention of thrombosis in kidney disease in patients with systemic lupus erythematosus and antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , 2019 , 13, 26-34	0.7	
22	[The Nephrological Aspects of the Use of Rivaroxaban and Other Direct Peroral Anticoagulants in Non-Valvular Atrial Fibrillation]. <i>Kardiologiya</i> , 2019 , 59, 60-69	1.5	
21	Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. <i>Respiratory Medicine</i> , 2020 , 57-83	0.2	
20	Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	0
19	Anticoagulation for atrial fibrillation in heart failure patients: balancing between Scylla and Charybdis. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 352-361	1.7	0
18	Anticoagulants in the Management of Pulmonary Embolism.		0
17	Temporal trends and in-hospital complications of catheter ablation for atrial fibrillation among patients with moderate and advanced chronic kidney diseases: 2005-2018.. <i>Journal of Cardiovascular Electrophysiology</i> , 2022 ,	2.7	1
16	Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation. <i>Rational Pharmacotherapy in Cardiology</i> , 2022 , 17, 916-926	0.5	
15	References. 2022 , 461-481		
14	Pharmacologic Agents Used to Reverse the Anticoagulant Effect of Common Anticoagulants.. <i>Southern Medical Journal</i> , 2022 , 115, 220-226	0.6	

13	Utilization of apixaban anti-Xa levels in transition from apixaban to warfarin in a patient with chronic renal dysfunction. <i>American Journal of Health-System Pharmacy</i> , 2021 ,	2.2	○
12	Chronic kidney disease and anticoagulation - Quick overview and practical guide. <i>Indian Journal of Vascular and Endovascular Surgery</i> , 2022 , 9, 40	0.1	
11	DataSheet_1.doc. 2020 ,		
10	Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease Relationships With Renal Function and Clinical Events. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	○
9	Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients. <i>Transplantation</i> , 2022 , 3, 208-218	1	
8	Hemorrhagic Versus Ischemic Risk in Patients with Atrial Fibrillation on Hemodialysis. 2022 ,		
7	Kidney function and the comparative effectiveness and safety of direct oral anticoagulants versus warfarin in adults with atrial fibrillation: a multicenter observational study.		○
6	Retrospective Comparison of Patients ≥80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant. 2022 , 43, 101130		○
5	Atrial Fibrillation and Hemodialysis Should we Anticoagulate These Patients? Ischemic Versus Hemorrhagic Risk. 2022 , 35, 757-759		○
4	Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study. 2022 , 10, 2566		○
3	Plasma apixaban levels in Chinese patients with chronic kidney disease Relationship with renal function and bleeding complications. 13,		○
2	Antithrombotic Management in Spine Surgery in the Elderly. 2023 , 19-49		○
1	Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation. 2023 ,		○